Baird Cuts Price Target on Theravance Biopharma (TBPH) Following 2Q15

August 11, 2015 10:20 AM

Baird maintained a Neutral rating on Theravance Biopharma (NASDAQ: TBPH), and cut the price target to $14.00 (from $17.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found